登录 | 注册    关注公众号  
微信公众号
搜索
 > 【B7-1】

B7-1信息

英文名称:Cluster of differentiation 80
中文名称:分化群80
靶点别称:Activation B7-1 antigen,LAB7,T-lymphocyte activation antigen CD80,CD80 Molecule,CD80 Antigen (CD28 Antigen Ligand 1, B7-1 Antigen),B-Lymphocyte Activation Antigen B7,CTLA-4 Counter-Receptor B7.1,CD28LG1,BB1,Costimulatory Molecule Variant IgV-CD80,Costimulatory Factor CD80,CD80 Antigen,B7-1,B7.1,B7-1 Antigen,B7,CD80,CD28LG
上市药物数量:2
临床药物数量:3
最高研发阶段:批准上市

B7-1产品列表

 
评论(9)
B71-H82F2|Biotinylated Human B7-1 / CD80 Protein, Fc,Avitag™ (MALS verified)
  1. 135XXXXXXX2
  2. 4人赞
  3. 在贵公司购买了这个CD80蛋白用来做elisa,筛选纯化后的单抗,做了阻断IC50实验,每次实验结果都能筛选出不同阻断效果的单抗,效果不错,经过蛋白电泳验证,结果显示稳定性也很好,很不错的一款产品。
  4. >
  5. 2021-09-01
B71-H5228|Human B7-1 / CD80 Protein, His Tag (MALS verified)
  1. 152XXXXXXX2
  2. 3人赞
  3. 使用过该蛋白做ELISA实验,将该CD80蛋白包被到孔板中,然后加入抗体分子与biotin-PDL1做blocking assay,可以获得理想的数据。
  4. >
  5. 2019-10-12
B71-H5228|Human B7-1 / CD80 Protein, His Tag (MALS verified)
  1. 182XXXXXXX2
  2. 3人赞
  3. 运用Acro家的B7-1与别家的CD28做BIL实验,亲和力不错,拟合结果相当好,R2达到了0.997,不错的产品。
  4. >
  5. 2020-01-10
 

B7-1 分子别名

CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7

B7-1 分子背景

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response.B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

B7-1 前沿进展

B7-1上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg 批准上市 百时美施贵宝 Nulojix EU 肾脏移植排斥 Bristol-Myers Squibb Pharma Eeig 2011-06-15 肾脏移植排斥, 器官移植排斥 详情
Abatacept 阿巴西普 ONO-4164; BMS-188667; BMS-188667SC; ONO-4164SC 批准上市 百时美施贵宝 Orencia United States 移植物抗宿主病 Bristol Myers Squibb Srlcompany 2005-12-23 关节炎, I型黏多糖贮积症, 免疫紊乱, 局灶性节段性肾小球硬化症, 再生障碍性贫血, 银屑病, 系统性红斑狼疮, 银屑病关节炎, 溃疡性结肠炎, 哮喘, 荨麻疹, Sjogren-Larsson综合征, 肌病, 普通可变性免疫缺陷, 关节痛, 风湿性多肌痛, 肾病综合征, 白细胞粘附缺陷综合征, 葡萄膜炎, 眼部疾病, 慢性肉芽肿病, 噬血细胞性淋巴组织细胞增多症, 弥漫性硬皮病, 心肌炎, 克罗恩病, 白塞病综合征, Kostmann综合征, 白癜风, 镰状细胞血症, 血小板机能不全, Sjtoegren综合征, 复发性多软骨炎, 抗中性粒细胞胞浆抗体相关性血管炎, 重症肌无力, 韦格纳肉芽肿, 威斯科特-奥尔德里奇综合征, 免疫球蛋白G4相关疾病, 斑秃, 巨细胞性动脉炎, 肌炎, 皮肌炎, 类风湿关节炎, 移植物抗宿主病, 强直性脊柱炎, 新型冠状病毒肺炎, 多发性肌炎, Chediak-Higashi综合征, β-地中海贫血, 范科尼贫血, 结节病, 系统性硬皮病 详情

B7-1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs 临床一期 湖南昭泰涌仁医疗创新有限公司 非小细胞肺癌 详情
Membrane bound ligand T-SIGn virus NG-348 临床一期 Psioxus Therapeutics Ltd 肿瘤 详情
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio) 临床一期 北京伟德杰生物科技有限公司 类风湿关节炎 详情
ASP-2408 ASP-2408 Maxygen 详情
rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA University Hospital Basel 详情
CTLA-4/FasL fusion protein (KAHR Medical) KAHR-102 Kahr Medical 详情
Belatacept biosimilar (Alphamab) KN-019 临床二期 苏州康宁杰瑞生物科技有限公司 肾脏移植排斥, 类风湿关节炎 详情

消息提示

请输入您的联系方式,再点击提交!

确定